Upending previous research, study finds no evidence of status-quo bias favoring standard care when two or more appropriate alternatives are presented.

Synthekine Inc., an engineered cytokine therapeutics company, today announced that the company has dosed the first patient in the SYNERGY-101 study. SYNERGY-101 is a global, randomized Phase 2 ...

Publication of Interim Results and Presentation at Recent Industry Event Demonstrate Clinical Benefit Associated with Use of ...

THE SKNJCT-003 CLINICAL STUDY EXPANSION INTO THE UNITED KINGDOM TO FURTHER ENABLE GLOBAL PATIENT RECRUITMENT AND CLINICAL DATASET TOWARD A PIVOTAL STUDY PROGRAM PHILADELPHIA, PA / ACCESS Newswire / ...

The American Academy of Pediatrics declined to recommend routine use of leucovorin for children with autism spectrum disorder ...

What study showed data for zanubrutinib in previously untreated CLL? Mazyar Shadman, MD, MPH: The SEQUOIA study was a larger ...

Self-administered hypnosis effectively alleviates hot flashes in menopausal women, enhancing quality of life and providing an ...

New research reveals that tirzepatide and semaglutide both offer strong, early heart-protective effects. A major new ...

CARDIAMP CMI Cohort Results -- In the open-label rolling cohort (n=5), patients saw an average 80-second increase in exercise ...

The ARTISTRY-1 Phase III trial demonstrated that a single-tablet regimen of bictegravir 75 mg/lenacapavir 50 mg maintains viral suppression and simplifies therapy for people living with HIV, ...

"Following standard angiography, microvascular angina was commonly misdiagnosed as noncardiac chest pain," he added. "Endotyping-informed therapy in the MRI-guided intervention group led to ...

Presented new subgroup analyses from phase 3 clinical trial of CAN-2409 in localized prostate cancer at the American Society ...